A preliminary quality of life questionnaire-bronchiectasis: A patient-reported outcome measure for bronchiectasis

Chest

Volumn 146, Issue 2, 2014, Pages 437-448

  Quittner, Alexandra L ^a   Marciel, Kristen K ^a   Salathe, Matthias A ^a   O'Donnell, Anne E ^b   Gotfried, Mark H ^c,d   Ilowite, Jonathan S ^e   Metersky, Mark L ^f   Flume, Patrick A ^g   Lewis, Sandra A ^h,i   McKevitt, Matthew ^h   Montgomery, A Bruce ^h   O'Riordan, Thomas G ^h   Barker, Alan F ^j  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Pulmonary Associates   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e WINTHROP UNIVERSITY HOSPITAL   (United States)

^f UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^h Gilead Sciences   (United States)

ⁱ Cardeas Pharma   (United States)

^j OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM;

ADULT; AGED; ARTICLE; BRONCHIECTASIS; CLINICAL ARTICLE; CONTENT VALIDITY; CONTROLLED STUDY; EMOTION; FEMALE; GRAM NEGATIVE BACTERIUM; HEALTH STATUS; HUMAN; INTERNAL CONSISTENCY; INTERVIEW; MALE; OPEN STUDY; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; QUALITY OF LIFE QUESTIONNAIRE BRONCHIECTASIS; QUESTIONNAIRE; SOCIAL INTERACTION; TEST RETEST RELIABILITY;

BRONCHIECTASIS; HEALTH STATUS; HUMANS; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; SELF REPORT;

EID: 84904000178     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-1891     Document Type: Article

References (38)

1. Nicotra MB, Rivera M, Dale AM, Shepherd R, Carter R. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest. 1995; 108 (4): 955-961.
2. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Gallagher M, Holmes PW. Outcome in adult bronchiectasis. COPD. 2005; 2 (1): 27-34. (Pubitemid 40776219)
3. King P, Holdsworth S, Freezer N, Holmes P. Bronchiectasis. I ntern Med J. 2006; 36 (11): 729-737. (Pubitemid 44563435)
4. O'Donnell AE. Bronchiectasis. Chest. 2008; 134 (4): 815-823.
5. Smith MP, Hill AT. Evaluating success of therapy for bronchiectasis: what end points to use? Clin Chest Med. 2012; 33 (2): 329-349.
6. Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med. 2000; 162 (2 pt 1): 481-485. (Pubitemid 30647187)
7. Lee AL, Button BM, Ellis S, et al. Clinical determinants of the 6-minute walk test in bronchiectasis. Respir Med. 2009; 103 (5): 780-785.
8. Eshed I, Minski I, Katz R, Jones PW, Priel IE. Bronchiectasis: correlation of high-resolution CT findings with health-related quality of life. Clin Radiol. 2007; 62 (2): 152-159. (Pubitemid 46039403)
9. Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MD, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax. 2003; 58 (4): 339-343. (Pubitemid 36411421)
10. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airfl ow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992; 145 (6): 1321-1327.
11. Murray MP, Turnbull K, MacQuarrie S, Pentland JL, Hill AT. Validation of the Leicester Cough Questionnaire in noncystic fibrosis bronchiectasis. Eur Respir J. 2009; 34 (1): 125-131.
12. Wilson CB, Jones PW, O'Leary CJ, Cole PJ, Wilson R. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med. 1997; 156 (2 Pt 1): 536-541. (Pubitemid 27351991)
13. Chan SL, Chan-Yeung MM, Ooi GC, et al. Validation of the Hong Kong Chinese version of the St. George Respiratory Questionnaire in patients with bronchiectasis. Chest. 2002; 122 (6): 2030-2037. (Pubitemid 36051140)
14. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987; 42 (10): 773-778. (Pubitemid 17142007)
15. Turner RR, Quittner AL, Parasuraman BM, Kallich JD, Cleeland CS; Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group. Patient-reported outcomes: instrument development and selection issues. Value Health. 2007; 10 (suppl 2): S86-S93. (Pubitemid 350098925)
16. Henry B, Aussage P, Grosskopf C, Goehrs JM. Development of the Cystic Fibrosis Questionnaire (CFQ) for assessing quality of life in pediatric and adult patients. Q ual Life Res. 2003; 12 (1): 63-76. (Pubitemid 36223007)
17. Quittner AL, Buu A, Messer MA, Modi AC, Watrous M. Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest. 2005; 128 (4): 2347-2354. (Pubitemid 41507578)
18. U.S. Department of Health and Human Services; Food and Drug Administration. Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER); Center for Devices and Radiological Health (CDRH). Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. US Food and Drug Administration website. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Published December 2009. Accessed August 26, 2013.
19. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine is effective in intensively-treated patients with cystic fibrosis. Am J Respir Crit Care Med. 2008; 178 (9): 921-928.
20. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest. 2009; 135 (5): 1223-1232.
21. Schwarz N, Sudman S. A nswering Questions: Methodology for Determining Cognitive and Communicative Processes in Survey Research. San Francisco, CA : Jossey-Bass; 1996.
22. Lessler JT, Forsyth BH. A coding system for appraising questionnaires. In: Schwarz N, Sudman S, eds. A nswering Questions: Methodology for Determining Cognitive and Communicative Process in Survey Research. San Francisco, CA : Jossey-Bass; 1996 : 259-292.
23. Quittner AL, Sweeny S, Watrous M, et al. Translation and linguistic validation of a disease-specific quality of life measure for cystic fibrosis. J Pediatr Psychol. 2000; 25 (6): 403-414.
24. Miller MR, Hankinson J, Brusasco V, et al; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005; 26 (2): 319-338. (Pubitemid 41079078)
25. Brody AS, Kosorok MR, Li Z, et al. Reproducibility of a scoring system for computed tomography scanning in cystic fibrosis. J Thorac Imaging. 2006; 21 (1): 14-21.
26. Ware J Jr, Brook RH, Davies-Avery A, et al. Conceptualization and measurement of health for adults in the health insurance study: vol 1, model of health and methodology. R-1987/1-HEW. Santa Monica, CA: Rand Corp; 1980. http://www.rand.org/pubs/reports/2006/R1987.1.pdf. Published May 1980. Accessed August 26, 2013.
27. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977; 33 (1): 159-174. (Pubitemid 8054849)
28. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics. Health, United States, 2005, with chartbook on trends in the health of Americans. Centers for Disease Control website. http://www.cdc.gov/nchs/data/hus/hus05.pdf. Accessed August 26, 2013.
29. Fayers P, Machin D. Q uality of Life. 2nd ed. Chichester, West Sussex, England : John Wiley & Sons, Ltd.; 2007 : 64.
30. Epstein JL, McPartland JM. The concept and measurement of the quality of school life. Am Educ Res J. 1976; 13 (1): 15-30.
31. European Medicines Agency (EMA) Committee for Medicinal Products for Human Use. (CHMP). Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. London, England: European Medicines Agency; 2005. http://www.ema. europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003637. pdf. Published July 27, 2005. Accessed August 26, 2013.
32. Bennett AV, Patrick DL, Lymp JF, Edwards TC, Goss CH. Comparison of 7-day and repeated 24-hour recall of symptoms of cystic fibrosis. J Cyst Fibros. 2010; 9 (6): 419-424.
33. Juniper EF, O'Byrne PM, Ferrie PJ, King DR, Roberts JN. Measuring asthma control. Clinic questionnaire or daily diary? Am J Respir Crit Care Med. 2000; 162 (4 pt 1): 1330-1334.
34. A study to see if AZLI (an inhaled antibiotic) is effective in treating adults with non-CF bronchiectasis-AIR-BX1. NCT01313624. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2011. http://clinicaltrials.gov/ ct2/show/NCT01313624. Updated August 26, 2013.
35. A study to see if AZLI (an inhaled antibiotic) is effective in treating adults with non-CF bronchiectasis-AIR-BX2. NCT01314716. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2011. http://clinicaltrials.gov/ ct2/show/NCT01314716. Updated August 26, 2013.
36. Barker A, O'Donnell A, Thompson PJ, et al. Two phase 3 placebo-controlled trials of aztreonam lysine for inhalation (AZLI) for non-cystic fibrosis bronchiectasis (NCFB) (abstract P4136). Eur Respir J. 2013; 42 (suppl 57): 877s-878s.
37. Quittner AL, Marciel KK, Barker AF. Quality of life questionnaire- bronchiectasis. University of Miami website. http://www.psy.miami.edu/qol-b/. Accessed August 26, 2013.
38. Olveira C, Olveira G, Espildora F, et al. Validation of a quality of life questionnaire for bronchiectasis: psychometric analyses of the Spanish QOL-B-V3.0 [published online ahead of print October 19, 2013]. Qual Life Res. doi:10.1007/s11136-013-0560-0.